• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    Presenting on the Emerging Growth Conference 72 Day 2 on June 13 Register Now

    6/12/24 7:00:00 AM ET
    $ASPI
    $ATRA
    $CIA
    $CLNN
    Major Chemicals
    Industrials
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care
    Get the next $ASPI alert in real time by email

    MIAMI, June 12, 2024 (GLOBE NEWSWIRE) -- EmergingGrowth.com a leading independent small cap media portal announces the schedule of the 72nd Emerging Growth Conference on June 12 & 13, 2024.

    The Emerging Growth Conference identifies companies in a wide range of growth sectors, with strong management teams, innovative products & services, focused strategy, execution, and the overall potential for long-term growth.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    For updates, follow us on Twitter

    Sponsors:

    QuoteMedia - Keep Investors Informed with Dynamic Plug and Play IR Solutions

    (844) 485-8200

    Sales@QuoteMedia.com

    www.QuoteMedia.com

    ProCore Advisory - Unleashing the power of strategic investor relations for public and pre-IPO companies

    (832)-847-1327

    pierre@procoreadvisory.com

    www.procoreadvisory.com

    Day 2

    June 13, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 - 9:35

    FBR, Ltd. (OTCQB:FBRKF) (ASX: FBR) 

    Keynote speaker: Michael John Pivac, CEO & Managing Director

    9:40 - 10:10

    Huize Holding Limited (NASDQQ: HUIZ)

    Keynote speaker: Mr. Ron Tam, Co CFO

    10:15 - 10:45

    Ascend Wellness Holdings Inc. (OTCQX:AAWH)

    Keynote speaker: Rebecca Koar, EVP of Investor Relations and Strategy

    10:50 – 11:20

    Targa Exploration Corp. (OTCQB:TRGEF) (CSE:TEX)

    Keynote speaker: Cameron Tymstra, President & CEO

      

    11:25 - 11:55

    Sucro Limited (TSXV:SUG) (OTCQB:SUGCF)

    Keynote speaker: Don Hill, Chairman

    12:00 – 12:30

    Patriot AG Corp.

    Keynote speaker: Eric Till, CEO / CFO, & Kyle Severson, COO

    12:35 – 1:05

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA)

    Keynote speaker: Jason Awe, Head of Corporate Communications & IR

    1:10 – 1:40

    Bioxytran, Inc. (OTCQB:BIXT)

    Keynote speakers: David Platt, CEO & Mike Sheikh, Executive Vice President Business Development

      

    1:45 - 2:15

    InMed Pharmaceuticals, Inc. (NASDAQ:INM)

    Keynote speaker: Eric Adams, CEO

    2:20 – 2:30

    Immuron Limited (NASDAQ:IMRN)

    Keynote speaker: Steve Lydeamore, CEO

    2:35 - 2:45

    Citizens, Inc. (NYSE:CIA)

    Keynote speakers: Gerald W. Shields, Vice Chairman and CEO Jeff Conklin, CFO

    2:50 – 3:00

    Digital Brand Media & Marketing Group, Inc. (OTC:DBMM)

    Keynote speaker: Reggie James, COO, Sr. VP & Exec. Director

    3:05 – 3:15

    ATRenew Inc. (NYSE:RERE)

    Keynote speakers: Jessie Jin, Investor Relations Manager & Jeremy Ji, Director of Corporate Development & Investor Relations

    3:20 - 3:30

    Meihua International Medical Technologies Co. (NASDAQ:MHUA)

    Keynote speaker: Mr. Steven Wang, CEO

    3:35 – 3:45

    GTI Energy, Ltd. (OTC:GTRIF) (ASX: GTR)

    Keynote speaker: Bruce Lane, Executive Director, CEO

    Presenting Today, June 12, 2024

    8:45

    Virtual Lobby opens.

    Register for the Conference. If you already registered, go back to the registration link and click "Already registered" and enter your email.

    9:00

    Introduction

    9:05 – 9:35

    Perfect Corp. (NYSE:PERF)

    Keynote speaker: Louis Chen, EVP, CSO

    9:40 - 10:10

    Intellabridge Technology Corporation (OTCQB:KASHF) (CSE:KASH)

    Keynote speaker: John Eagleton, CEO

    10:15 - 10:45

    Pulsar Helium, Inc.'s (OTCQB:PSRHF) (TSXV:PLSR)

    Keynote speaker: Thomas Abraham-James President / CEO

    10:50 - 11:20

    Cadrenal Therapeutics, Inc. (NASDAQ:CVKD)

    Keynote speaker: Mr. Quang X. Pham, Chairman & CEO

    11:25 - 11:55

    LogicMark, Inc. (NASDAQ:LGMK)

    Keynote speaker: Ms. Chia-Lin Simmons, CEO

      

    12:00 - 12:30

    Unusual Machines, Inc. (NYSE:UMAC)

    Keynote speaker: Allan Evans, CEO

    12:35 - 1:05

    SeaStar Medical Holding Corporation (NASDAQ:ICU)

    Keynote speaker: Eric Schlorff, President / CEO, Director

    1:10 - 1:40

    Diakonos Oncology, Inc.

    Keynote speakers: Jay Hartenbach, COO, & Anthony Baldor, CFO & Head of Business Development

    1:45 - 2:15

    Longeveron, Inc. (NASDAQ:LGVN)

    Keynote speaker: Mohamed Wa'el Hashad, CEO & Director

    2:20 - 3:00

    Clene Inc., (NASDAQ:CLNN)

    Keynote speaker: Rob Etherington, President / CEO, & Morgan Grown, CFO

    Postponed to July

    Regen BioPharma Inc. (OTC:RGBP)

    Keynote speakers: David Koos, President / CEO, and Harry M. Lander, Ph.D. Senior Scientific Consultant

    3:20 - 3:30

    SenesTech, Inc. (NASDAQ:SNES)

    Keynote speaker: Joel L. Fruendt, President, CEO, & Director

    3:35 - 4:05

    ASP Isotopes Inc. (NASDAQ:ASPI)

    Keynote speaker: Paul Elliot Mann, CEO

    Visit the following link to register. You will then receive an email containing the link and time to sign into the conference.

    Register for the Conference here.

    Submit Questions for any of the presenting companies to:

    Questions@EmergingGrowth.com

    Replays: Subscribe to our YouTube Channel

    About EmergingGrowth.com

    Founded in 2009, Emerging Growth.com quickly became a leader in its space and has developed an extensive history of identifying emerging growth companies that can be overlooked by the investment community.

    About the Emerging Growth Conference

    The Emerging Growth Conference is an effective way for public companies to engage with the investment community regarding their Company, new products, services and other major announcements from anywhere, in an effective and time efficient manner.

    All sessions are conducted through video webcasts. Our conference serves as a vehicle for Emerging Growth to build relationships with our existing and potential clients.  Accordingly, a certain number of the presenting companies are our current clients, and some may become our clients in the future.  In exchange for services we provide, our clients pay us fees in the form of cash and securities, and we may currently have, or in the future may have investments in the securities of certain of the presenting companies. Finally, certain of the presenting companies have paid us a fee to secure a presentation time slot or to present generally. The presentations to be delivered by the presenting companies (including any virtual handouts of written materials) have not been approved, endorsed by or otherwise reviewed by EmergingGrowth.com nor should they in any way be construed to have been made in connection with an offer to sell or a solicitation of an offer to buy securities. Please consult an investment professional before investing in anything viewed on the Emerging Growth Conference or on EmergingGrowth.com.

    If you believe or know of a company that might fit our audience, contact us here.

    Thank you for your interest in our conference, and we look forward to your participation in future conferences.

    Contact:

    Emerging Growth

    Phone: 1-305-330-1985

    Email: Conference@EmergingGrowth.com



    Primary Logo

    Get the next $ASPI alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ASPI
    $ATRA
    $CIA
    $CLNN

    CompanyDatePrice TargetRatingAnalyst
    ATRenew Inc.
    $RERE
    7/21/2026$5.50Buy
    UBS
    Unusual Machines Inc.
    $UMAC
    7/15/2026$42.00Buy
    H.C. Wainwright
    Unusual Machines Inc.
    $UMAC
    5/15/2026$20.00 → $22.00Buy
    Needham
    Unusual Machines Inc.
    $UMAC
    5/13/2026$25.00Buy
    Roth Capital
    Atara Biotherapeutics Inc.
    $ATRA
    5/8/2026$13.00Hold → Buy
    Canaccord Genuity
    Atara Biotherapeutics Inc.
    $ATRA
    1/13/2026$6.00Buy → Hold
    Canaccord Genuity
    ASP Isotopes Inc.
    $ASPI
    12/4/2025$13.00Overweight
    Cantor Fitzgerald
    Unusual Machines Inc.
    $UMAC
    8/19/2025$15.00Buy
    Needham
    More analyst ratings

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Large owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/17/26 7:29:29 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Vivo Opportunity, Llc bought $31,846 worth of shares (20,546 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/16/26 9:58:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Chief Executive Officer Edell Michael bought $1,430 worth of shares (1,000 units at $1.43), increasing direct ownership by 25% to 5,000 units (SEC Form 4)

    4 - SenesTech, Inc. (0001680378) (Issuer)

    7/8/26 5:01:03 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    New insider Washburn Marie claimed ownership of 101,030 shares (SEC Form 3)

    3 - Longeveron Inc. (0001721484) (Issuer)

    7/21/26 6:00:04 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Adar1 Capital Management, Llc bought $1,555 worth of shares (1,000 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/17/26 7:29:29 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Large owner Vivo Opportunity, Llc bought $31,846 worth of shares (20,546 units at $1.55) (SEC Form 4)

    4 - InMed Pharmaceuticals Inc. (0001728328) (Issuer)

    7/16/26 9:58:22 PM ET
    $INM
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    ASP Isotopes Announces Quantum Leap Energy Research Agreement with Texas A&M Engineering Experiment Station to Advance Uranium Conversion Technology

    DALLAS, July 21, 2026 (GLOBE NEWSWIRE) -- ASP Isotopes Inc. (NASDAQ:ASPI) ("ASPI") today announced that Quantum Leap Energy LLC ("we," "QLE" or the "Company"), a wholly-owned subsidiary of ASPI dedicated to advancing innovative technologies and processes across critical segments of the fission and fusion nuclear fuel cycle, has signed a research agreement with the Texas A&M Engineering Experiment Station (TEES) to advance and de-risk the commercial production of high-purity uranium hexafluoride (UF6), a critical feedstock in the existing nuclear fuel enrichment supply chain. This agreement reflects the growing momentum across Texas' nuclear industry and highlights the value of collaboratio

    7/21/26 8:00:00 AM ET
    $ASPI
    Major Chemicals
    Industrials

    Cadrenal Therapeutics Launches Partnering Process as Its Cardiac Acute Critical Care Assets Advance to Transaction Readiness Following Landmark ISTH Data Presentation

    Capital-efficient strategy focuses on differentiated therapies for cardiac pre- and post-operative critical care and orphan cardiovascular conditionsCompany is exploring development, licensing, and commercialization partnerships for CAD-1005, frunexian, and tecarfarinRecently presented Phase 2 CAD-1005 data demonstrated a >25% absolute reduction in thrombotic events in patients with heparin-induced thrombocytopenia PONTE VEDRA, Fla., July 21, 2026 (GLOBE NEWSWIRE) -- Cadrenal Therapeutics, Inc. (NASDAQ:CVKD), a late-stage biopharmaceutical company advancing specialized therapies for critical care cardiology and orphan cardiovascular conditions, today announced a comprehensive alignment of

    7/21/26 8:00:00 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Immuron CEO, Steven Lydeamore presentation at Kalkine Media Webinar

    MELBOURNE, Australia, July 20, 2026 (GLOBE NEWSWIRE) -- Immuron Limited ((ASX: IMC, NASDAQ:IMRN) is pleased to advise our Chief Executive Officer, Steven Lydeamore is presenting virtually at the Kalkine Media Webinar on Monday, 20th July 2026 (12:30pm Australian Eastern Time). A copy of the presentation slide deck is available on the Company’s website: https://investors.immuron.com.au/announcements/7639968 This release has been authorised by the directors of Immuron Limited. COMPANY CONTACT:Steven LydeamoreChief Executive Officersteve@immuron.com           About ImmuronImmuron Limited ((ASX: IMC, NASDAQ:IMRN), is an Australian biopharmaceutical company focused on developing and commerci

    7/20/26 6:00:00 AM ET
    $IMRN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    UBS initiated coverage on ATRenew with a new price target

    UBS initiated coverage of ATRenew with a rating of Buy and set a new price target of $5.50

    7/21/26 8:08:04 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    H.C. Wainwright initiated coverage on Unusual Machines with a new price target

    H.C. Wainwright initiated coverage of Unusual Machines with a rating of Buy and set a new price target of $42.00

    7/15/26 8:52:44 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    Needham reiterated coverage on Unusual Machines with a new price target

    Needham reiterated coverage of Unusual Machines with a rating of Buy and set a new price target of $22.00 from $20.00 previously

    5/15/26 7:50:30 AM ET
    $UMAC
    Radio And Television Broadcasting And Communications Equipment
    Technology

    $ASPI
    $ATRA
    $CIA
    $CLNN
    SEC Filings

    View All

    SEC Form S-8 filed by SeaStar Medical Holding Corporation

    S-8 - SeaStar Medical Holding Corp (0001831868) (Filer)

    7/21/26 4:02:06 PM ET
    $ICU
    Medical/Dental Instruments
    Health Care

    Cadrenal Therapeutics Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits

    8-K - Cadrenal Therapeutics, Inc. (0001937993) (Filer)

    7/21/26 8:30:30 AM ET
    $CVKD
    Biotechnology: Pharmaceutical Preparations
    Health Care

    ASP Isotopes Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - ASP Isotopes Inc. (0001921865) (Filer)

    7/21/26 8:05:13 AM ET
    $ASPI
    Major Chemicals
    Industrials

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Leadership Updates

    Live Leadership Updates

    View All

    Longeveron® Appoints Marie Washburn as Chief Financial Officer

    Ms. Washburn has over 20 years of experience in leadership roles in the pharmaceutical and biotech sectorsCorporate focus on delivering top-line results from the Phase 2b clinical trial evaluating its stem cell therapy in Hypoplastic Left Heart Syndrome (HLHS), anticipated in the third quarter of 2026 MIAMI, July 06, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN) a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic aging-related conditions, today announced that the Company has appointed Marie Washburn to the Company’s executive leadership team in the role of Senior Vice President and Chief Financial Officer ("CFO"), p

    7/6/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SenesTech Appoints Jack Karabees as Executive Vice President of Sales

    Veteran enterprise sales executive brings decades of experience scaling companies and leading successful commercial organizationsSURPRISE, Ariz., June 29, 2026 /PRNewswire/ -- SenesTech, Inc. (NASDAQ:SNES), a leader in fertility control solutions for managing rodent populations, today announced the appointment of Jack Karabees as Executive Vice President of Sales. Mr. Karabees brings more than three decades of experience building and leading professional B2B sales organizations and helping companies define the processes and systems necessary to achieve significant scale. In his

    6/29/26 8:30:00 AM ET
    $SNES
    $TDOC
    Agricultural Chemicals
    Industrials
    Medical/Nursing Services
    Health Care

    Atara Biotherapeutics Announces Changes to Its Board of Directors

    Atara Biotherapeutics, Inc. (NASDAQ:ATRA), a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced the departure of Carol Gallagher, Pharm D from its Board of Directors. "On behalf of Atara and its Board of Directors, I want to express my gratitude to Carol for her dedication to our company and its shareholders over the past thirteen years," said Cokey Nguyen, President and Chief Executive Officer of Atara. "Carol has been a pillar on the Board of Directors serving in multiple roles over the course of her tenure. We wish Carol continued s

    6/12/26 4:00:00 PM ET
    $ATRA
    Biotechnology: Biological Products (No Diagnostic Substances)
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Financials

    Live finance-specific insights

    View All

    ATRenew Inc. Reports Unaudited First Quarter 2026 Financial Results

    SHANGHAI, May 19, 2026 /PRNewswire/ -- ATRenew Inc. ("ATRenew" or the "Company") (NYSE:RERE), a pioneer in technology-driven recycling and trade-in solutions for consumer products in China, today announced its unaudited financial results for the three months ended March 31, 2026. First Quarter 2026 HighlightsTotal net revenues grew by 32.4% to RMB6,160.1 million (US$893.0 million) from RMB4,653.5 million in the same period of 2025.Income from operations increased by 154.9% to RMB185.3 million (US$26.9 million) from RMB72.7 million in the same period of 2025. Adjusted income from operations (non-GAAP)[1] grew by 70.2% to RMB190.5 million (US$27.6 million) from RMB111.9 million in the same per

    5/19/26 4:00:00 AM ET
    $RERE
    Other Specialty Stores
    Consumer Discretionary

    LogicMark, Inc. Announces Strong First Quarter 2026 Results

    LOUISVILLE, Ky., May 13, 2026 (GLOBE NEWSWIRE) -- LogicMark, Inc. (OTC:LGMK) (the "Company"), a provider of personal safety and emergency response systems (PERS), health communications devices, and technology for the growing care and safety economy, today announced financial and operational results for the first quarter ended March 31, 2026. Financial Highlights First quarter 2026 revenue increased 24% to $3.2 million compared to the same period last year. Revenue has increased year-over-year in seven of the last eight quarters.Gross margin expanded 610 basis points to 69.6%, up from 63.5% in the prior-year period.Total operating expenses declined 7% to $3.7 million, compared with $4.0 m

    5/13/26 4:05:00 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Longeveron Announces 2026 First Quarter Financial Results and Provides Business Update

    On track for August 2026 top-line results from Phase 2b clinical trial (ELPIS II) evaluating laromestrocel as a potential adjunct treatment for hypoplastic left heart syndrome, a rare pediatric disease and orphan-designated indicationClosed a private placement of up to $30 million, with $15 million funded in the initial closing, led by Coastlands Capital with participation from Janus Henderson Investors and other healthcare focused fundsCompany to host conference call and webcast today at 4:30 p.m. ET MIAMI, May 13, 2026 (GLOBE NEWSWIRE) -- Longeveron Inc. (NASDAQ:LGVN), a clinical stage biotechnology company developing cellular therapy for life-threatening, rare pediatric and chronic agi

    5/13/26 4:05:00 PM ET
    $LGVN
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $ASPI
    $ATRA
    $CIA
    $CLNN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13D/A filed by LogicMark Inc.

    SC 13D/A - LogicMark, Inc. (0001566826) (Subject)

    12/3/24 3:35:39 PM ET
    $LGMK
    Industrial Specialties
    Health Care

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:28:08 PM ET
    $SNES
    Agricultural Chemicals
    Industrials

    Amendment: SEC Form SC 13G/A filed by SenesTech Inc.

    SC 13G/A - SenesTech, Inc. (0001680378) (Subject)

    11/14/24 7:12:23 PM ET
    $SNES
    Agricultural Chemicals
    Industrials